The incidence, risk, clinical characteristics and mechanism of CIP for anti-PD-1/PD-L1 monotherapy or a combination with other therapies (radiotherapy, chemotherapy or targeted therapy) may differ, which might influence the subsequent treatment options and prognosis of CIP (12). Here, CD274 is linked to hereditary sensory and autonomic neuropathy.